title: Efficacy and safety of secukinumab in the treatment of moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.
abstract: Psoriasis is a chronic inflammatory skin disease with high rate of recurrence. New anti-interleukin-17 (IL-17) and anti-IL17RA biologics are in Phase 3 clinical trials and may prove to be more effective than existing biologic drugs. Now we perform a meta-analysis on efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis. In this meta-analysis, data analysis was performed with the Cochrane Collaboration's RevMan 5.0 software. Eight randomized controlled trials (RCTs) with a total of 3,213 psoriasis cases were included in the meta-analysis. Co-primary endpoints (week 12) were ≥ 75%/90% improvement in psoriasis area and a score of 0 (clear) or 1 (almost clear) on a 5-point Investigator's Global Assessment scale (IGA mod 2011 0/1) versus placebo [1]. The overall efficacy in the meta-analysis was as follows: PASI 75: for secukinumab 150 mg versus placebo, fixed-effects OR = 49.25, 95% CI: 33.67-72.06, Z = 20.07, P < 0.00001; PASI 90: for secukinumab 150 mg versus placebo, fixed-effects OR = 44.92, 95% CI: 24.72-81.62, Z = 12.49, P < 0.00001; IGA mod 2011 0/1: for secukinumab 150 mg versus placebo, random-effects OR = 22.25, 95% CI: 7.63-64.84, Z = 5.68, P < 0.00001; Compared with placebo, there were no significant adverse effects in the secukinumab groups, demonstrating safety in the treatment of moderate to severe plaque psoriasis. The proportion of patients who achieved 75%, 90% and IGA mod 2011 0/1 reductions respectively was significant in the secukinumab groups, demonstrating a rapid clinical improvement accompanied by a favorable short-term safety profile.
authors.affiliation: Department of Dermatology, Shanghai Tenth People's Hospital, Tongji University School of Medicine Shanghai 200072, China ; The First Affiliated Hospital of Soochow University Suzhou 215000, Jiangsu Province, China.
authors.forename: Hui-Zi
authors.initials: HZ
authors.lastname: Xiong
authors.affiliation: Department of Dermatology, Shanghai Tenth People's Hospital, Tongji University School of Medicine Shanghai 200072, China.
authors.forename: Jun-Ying
authors.initials: JY
authors.lastname: Gu
authors.affiliation: Department of General Surgery, Shanghai Tenth People's Hospital, Tongji University School of Medicine Shanghai 200072, China.
authors.forename: Zhi-Gang
authors.initials: ZG
authors.lastname: He
authors.affiliation: Department of Dermatology, Shanghai Tenth People's Hospital, Tongji University School of Medicine Shanghai 200072, China.
authors.forename: Wen-Juan
authors.initials: WJ
authors.lastname: Chen
authors.affiliation: Department of Clinical Laboratory Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine Shanghai 200072, China.
authors.forename: Xiao
authors.initials: X
authors.lastname: Zhang
authors.affiliation: Department of Clinical Laboratory Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine Shanghai 200072, China.
authors.forename: Jia-Yi
authors.initials: JY
authors.lastname: Wang
authors.affiliation: Department of Dermatology, Shanghai Tenth People's Hospital, Tongji University School of Medicine Shanghai 200072, China.
authors.forename: Yu-Ling
authors.initials: YL
authors.lastname: Shi
keywords: Psoriasis; meta-analysis; secukinumab